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ABSTRACT. A new 20% safflower oil fat emulsion was com-
pared with its 10% counterpart in a small series of pediatric
patients. Five infants and children, studied for a 2-week period,
received either the 10% or 20% emulsion for 1 week and the
other emulsion the 2nd week. No serious toxicity or side effects
were noted in any of the patients following the infusion of either
emulsion. In addition, significant weight gain was noted in the
children, and clinical improvement was apparent in all cases.
This preliminary study suggests that the 20% Liposyn is as safe
and effective as its 10% counterpart.
Intravenously administered fat emulsions are an im-
portant component of any program of total parenteral
nutrition (TPN). In addition to providing essential fatty
acids, they offer a concentrated source of energy sub-
strate in an isotonic solution. These characteristics make
them particularly useful in the infant in whom glucose
intolerance and renal function limitations may contrain-
dicate the sole use of large volume glucose and amino
acid (AA) solutions for intravenous nutrition.’
Peripherally-administered TPN regimens consisting
solely of glucose and AA supply insufficient calories for
growth unless massive volumes of fluid are given.’ The
addition of a fat emulsion which will provide 30-50% of
the total caloric requirements makes peripherally-admin-
istered TPN far more practical and attractive. 3,4
Having safely tested a new safflower oil emulsion (Li-
posyn-10%, Abbott Laboratories, Chicago, IL) in a small
group of pediatric patients, we proceeded to compare this
10% safflower oil emulsion with one which is twice as
concentrated (Lipsoyn-20%).‘’ The obvious advantage of
the 20% emulsion over the 10% preparation is the provi-
sion of the same number of calories in half the volume.
In infants, in whom fluid tolerance is critical, Liposyn
20% would allow significant reductions in total fluid
volume without compromising caloric input.
This study was undertaken to compare the toxicity
and efficacy of the 20% with 10% Liposyn over a 2-wk
period. The results document the improved nutritional
status and weight gain of the patients studied with no
adverse side effects or toxicity attributable to either lipid
emulsion.
MATERIALS AND METHODS
This study was conducted at the Mott Children’s Hos-
pital, Unversity of Michigan Medical Center, from No-
vember 1979 through March 1980, in infants and children
from 1 day to 12 yr of age who required TPN for at least
14 days. Patients receiving any enteral nutrition and
those demonstrating disturbances in normal fat metab-
olism such as pathological hyperlipemia, lipoid necrosis
or acute pancreatitis accompanied by hyperlipemia were
excluded from the study. Five pediatric patients com-
pleted the study. Their summary histories follow and
their nutritional status is presented in Table I.
Patient #1, a 4-day-old, 2.6 kg, white female who
underwent an esophagostomy and gastrostomy for
esophageal atresia without tracheoesophageal fistula. Pa-
tient #2, a 1-day-old, 1.7 kg, white female underwent a
primary repair of an esophageal atresia with tracheo-
esophageal fistula. Patient #3, a 12-yr-old, 56.8 kg, white
female with ulcerative colitis and severe rectal bleeding,
underwent a subtotal colectomy and ileostomy. Patient
#4, a 2-wk-old, 1.9 kg, white female underwent a colec-
tomy for perforated necrotizing enterocolitis. Patient #5,
a newborn, 2.3 kg, white male with a gastroschisis, was
treated with a staged procedure.
After parental informed consent was obtained, the
following preinfusion tests were performed: urinalysis,
complete blood count with differential white blood cell
count, platelet count, blood urea nitrogen, serum uric
acid, albumin, total protein, cholesterol, triglycerides,
total bilirubin, alkaline phosphatase, LDH, and SGOT.
Subclavian vein catherization was performed on patient
#3. while nerinheral venous access was established in the
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remaining patients. All 5 patients were started on a
program of glucose, AA, and a safflower oil emulsion
(Liposyn) at a concentration of either 10 or 20%. The
study was divided into 2 periods of 7 days each. During
the 1st wk, one of the fat emulsions (10 or 20%) provided
one-third to one-half of the patient’s total daily caloric
requirements (TDCR). During the second 7-day period,
the alternate fat emulsion was substituted in the feeding
regimen, supplying the same number of calories as the
first fat emulsion. Thus, patients #1, #4, and #5 received
Liposyn 20% during the 1st wk while patients #2 and
#3 received Liposyn 10% during the 1st wk. The emulsion
was infused through a Y-connector into the line contain-
ing the glucose-AA solution and the infusion was admin-
istered continuously over the 24-hr period.
The solution used for centrally administered TPN
consisted of 25% glucose and 3.5% crystalline AA (Ami-
nosyn, Abbott Laboratories, Chicago) while the periph-
eral regimen consisted of 12.5% glucose and 2.5% crystal-
line AA. The TPN solution also contained routine vi-
tamin and mineral additives which are summarized in
Table II.
Each 100 ml of Liposyn-10% contains 10 g safflower oil,
1.2 g emulsifying agent, an egg phosphatide, and 1.2 g
glycerine to make the solution isotonic (340 mOsm/liter).
Liposyn-20% differs only in that it contains 20 g safflower
oil/100 cc solution. Sodium hydroxide is used to adjust
the pH of both solutions between 5.0 and 9.0. Liposyn-
10% provides 1.1 kcal/ml; Liposyn-20% provides 2.0 kcal/
ml. The fatty acid composition of this emulsion is listed
in Table III.
Table IV summarizes the TPN treatment of these
patients and includes calculations of the amount of the
various nutrients provided during each weekly period.
Daily observations included vital signs, weight, and a
report of adverse symptoms or side effects. Estimated
caloric requirements were computed daily and were com-
pared to calories actually received. At weekly intervals,
the initial battery of blood and urine tests were repeated
and an assessment was made of any changes in the
patient’s nutritional status.
RESULTS
All patients gained weight (Tables I and IV) during the
course of the study. The per cent change during the 20%
lipid sequence was 5.0 ± 3.1 compared with 9.2 ± 1.8
during the 10% sequence, a highly significant difference.
The total weight gain from baseline of the end of the
study period was 14.6 ± 3.4%, a significant increase from
initial levels.
All patients started the study with abnormally low
serum albumin levels (Table V). The only one to achieve
T ABLE II
Guidelines for TPS additiL’es
í&dquo; -.- - -- 1. L- ...._-~-- .,. L_-
&dquo; MVI concentrate (US Pharmaceutical Corporation)-each 5 ml
contains: ascorbic acid, 500 mg; vitamin A, 10,000 IU; vitamin D, 1,000
IU; thiamine, 50 mg; riboflavin, 10 mg; pyridoxine, 15 mg; niacin, 100
mg; dexpanthenol, 25 mg; and vitamin E, 5 IU.
b Trace element solution (manufactured by University of Michigan
Pharmacy Department)-each ml contains: zinc, 2 mg (0.060 mEq);
copper, 0.4 mg (0.030 mEq); manganese, 0.2 mg (0.015 mEq); and iodide,
0.056 mg (0.00044 mEq).
TABLE III
Fatty acid composition of different fat emulsions
- . ~ . . -.
&dquo; Essential fatty acid.
normal levels during either lipid regimen was patient #3
(sequence 10-20). The remaining patients finished both
sequences with serum albumin levels below the normal
range.
Baseline triglyceride levels (Table V) were normal in
all patients; no initial value was obtained for patient #1.
Patients #1, #4, and #5 (sequence 20-10) had triglyceride
levels which were 1.0, 1.9, and 1.0 times normal, respec-
tively, at the end of the 20% sequence, and triglyceride
levels which were 1.1, 1.1, and 2.2 times normal, respec-
tively, at the conclusion of the 10’% sequence. Patients
#2 and #3 (sequence 10-20) completed the 10% regimen
with triglyceride levels which were 1.2 and 1.0 times
normal; both patients finished the 20% period with nor-
mal triglyceride values.
Blood urea nitrogen remained within the normal range
in patients #1, #5 (sequence 20-10) and #2 (sequence 10-
20) throughout both courses of therapy (Table V). Pa-
tient #4 had a baseline value of 1.2 times normal which
returned to the normal range during the study period.
Patient #3 (sequence 10-20) had abnormally low blood
urea nitrogen values, 35 and 30% below normal, at the
conclusion of the 10 and 20% sequences, respectively.
Patients #1, #4 and #5 (sequence 20-10) started the
study with baseline SGOT levels (Table V) which were
2.2, 3.9, and 5.0 times normal, respectively, and concluded
the 20% sequence with values which were 1.1, 1.0, and 2.8
times normal. They completed the 10% regimen with
levels of 1.0, 1.9, and 1.7 times normal. Patients #2 and
#3 (sequence 10-20), with baseline measurements of 2.0
and 1.0 times normal, finished the 10% sequence with
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TABLE IV
Auerage daily nutritional components
TABLE V
Levels achieved with the two regimen
SGOT levels 1.8 and 1.2 times normal and completed the
20% sequence with SGOT values of 1.1 and 1.2 times
normal, respectively.
Patients #1, #4 and #5 (sequence 20-10), with baseline
LDH measurements of 2.5, 4.5, and 7.5 times normal,
respectively, concluded the 20% period with values of 1.6,
2.9, and 2.5 times normal and the 10% sequence at 1.9,
3.6, and 2.4 times normal (Table V). Patient #3 (sequence
10-20) remained in the normal range during the entire
study period. Patient #2 (sequence 10-20), who had a
baseline LDH measurement of 3.4 times normal, finished
the 20% sequence at 4.0 times normal and the 10%
sequence at 2.7 times normal.
All patients except #3 exhibited abnormal alkaline
phosphatase levels (Table V) during the course of the
study. Patients #1, #4, and #5 (lipid sequence 20-10),
who had baseline alkaline phosphatase levels of 1.3, 1.2,
and 1.3 times normal, concluded the 20% regimen at 1.6,
1.8, and 2.2 times normal and the 10% sequence with
levels 2.3, 2.6, and 1.8 times normal, respectively. Patient
#2 ended the 10% sequence at 3.0 times normal and the
20% period at 4.3 times normal.
All patients except number # 3 had abnormal bilirubin
values during the study (Table V). Patients #1, #4, and
#5 (sequence 20-10), who had baseline measurements of
10.6, 2.3, and 5.2 times normal, respectively, ended the
20% sequence at 2.2, 1.0, and 4.2 times normal and the
10% regiment at 1.0, 2.3, and 9.1 times normal. Patient
#2 (sequence 10-20) who had a baseline value of 1.7 times
normal, completed the 10% sequence at 3.0 times normal
and the 20% period at 4.3 times normal.
DISCUSSION
Although the use of the fat emulsions as a component
of a parenteral nutrition program is well accepted, the
varied biological activity of different fat emulsions makes
it difficult to generalize about their toxicity and efficacy.6
Fat emulsions have different combinations of fatty acids
and the effect of such combinations on the nutritional
efficacy of the solution are not known. Both the 10 and
20% offer a theoretical advantage of having a higher
percentage of essential fatty acids (linoleic acidS) than
any other commercially available fat emulsions. Studies
thus far, including the present one, have not provided
data indicating any advantage from this high concentra-
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tion of linoleic acid. A previous report from this institu- <
tion verified that no serious side effects or toxicity oc- ]
curred in a small group of children who received 10% ]
Liposyn as part of their nonprotein caloric requirements.’ i
The present study was designed to compare the same fat i
emulsion in a 10 and 20% form with regard to toxicity i
and therapeutic effectiveness. <
In none of the patients could any difference be detected
clinically following the infusion of the 10 or 20% emulsion.
However, there was a significantly greater weight gain
following the 10%. emulsion in this small series of children.
This difference was statistically significant even in this
small group of patients. No other significant differences
in the nutritional effects of the emulsion were noted. The
only other difference noted between the 10 and 20%
emulsion was a lower triglyceride level following the 20%
sequence, but this was not statistically significant. Except
for a mild elevation in alkaline phosphatase, no signifi-
cant abnormalities in the liver function tests were noted
during this 2-wk period. The alkaline phosphatase ele-
vation has been noted in other series of patients treated
both with and without fat emulsions.’
Changes in serum cholesterol and triglycerides with
different fat emulsions have been variable, and the small,
transient elevations in serum triglycerides noted in this
study are consistent with previous findings for other
preparations.8,9 No instance of the &dquo;overloading syn-
drome&dquo; was observed even though this has been reported
with other preparations, especially cottonseed emul-
sions.1o Although the period of study was probably too
short, no evidence of fatty acid deficiency was observed
in any of the 5 children.
Except for the slightly greater weight gain noted with
the 10% emulsion, no significant difference between the
10 and 20% preparation was noted in this small group of
~hildren with regard to toxicity or efficacy. Furthermore,
zo serious side effects or toxicity occurred in any of the
patients, and all gained weight and improved clinically
during the 2-ii’k study. These data support the conclusion
that both the 10 and 20 ~ safflower oil emulsions are safe
and effective in a parenteral nutrition program for chil-
dren.
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